Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners analyst Will Soghikian initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $40.
Leerink Partners analyst Will Soghikian initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $40.